ReviewBrain, behavior, & immunity - health2020
Microbial metabolites and immune regulation: New targets for major depressive disorder.
Review in Brain, behavior, & immunity - health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Roseburia intestinalis ameliorates adolescent depression via GPR43‑dependent Treg cell expansion and suppression of neuroinflammation.Journal of neuroinflammation · 2026Article
- Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities.Mini reviews in medicinal chemistry · 2026Review
- The emerging role of microbiota derived SCFAs in neurodegenerative disorders.Brain, behavior, & immunity - health · 2025Review
- The cancer-immune dialogue in the context of stress.Nature reviews. Immunology · 2024Review
- Lactobacillus from the Altered Schaedler Flora maintain IFNγ homeostasis to promote behavioral stress resilience.Brain, behavior, and immunity · 2024Article
- The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies.Current pharmaceutical biotechnology · 2024Review
- Benzophenones-natural metabolites with great Hopes in drug discovery: structures, occurrence, bioactivities, and biosynthesis.RSC advances · 2023Review
- The activity of the aryl hydrocarbon receptor in T cells tunes the gut microenvironment to sustain autoimmunity and neuroinflammation.PLoS biology · 2023Article
- Review
- Deletion of ghrelin alters tryptophan metabolism and exacerbates experimental ulcerative colitis in aged mice.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Stress-induced despair behavior develops independently of the Ahr-RORγt axis in CD4 + cells.Scientific reports · 2022Article
- Reviewing the role of gut microbiota in the pathogenesis of depression and exploring new therapeutic options.Frontiers in neuroscience · 2022Review
- Tumor microbiome metabolism: A game changer in cancer development and therapy.Frontiers in oncology · 2022Review
- Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment.Frontiers in neuroscience · 2022Review
- MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Treatments for depression and mood disorders have been singularly targeted at the brain without consideration for the context of the rest of the body. As evidence mounts for a role of autoimmunity and inflammation as risk factors and contributors to mood disorders, attention has shifted to one of the primary immunoregulatory organs in the body--the gut. Gut-brain interactions have been established and correlative links between the microbiome and mood have been examined, but with novel tools and a base of understanding, focus shifts to the mechanisms of these communications. In this review, we examine how the small molecules produced by metabolic processes of bacteria in the gut influence the host immune system. The gaps in knowledge discussed here include the under characterized diversity of small molecules crossing the gut walls, as well as the need to close the logical loop connecting the microbiome to the immune system, and the immune system to behavior and mood. As we move past the dawn of this field, more precise understanding using novel tools and techniques will help move toward a more informed and systematic process for clinically evaluating the efficacy of probiotics and bacterially derived compounds as antidepressants and mood regulators.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.